Re-Analysis Shows Screening Reduces Prostate CA Mortality

Share this content:
Re-Analysis Shows Screening Reduces Prostate CA Mortality
Re-Analysis Shows Screening Reduces Prostate CA Mortality

TUESDAY, Sept. 5, 2017 (HealthDay News) -- Re-analysis of evidence suggests that screening does reduce prostate cancer mortality, according to a study published online Sept. 4 in the Annals of Internal Medicine.

Alex Tsodikov, Ph.D., from the University of Michigan in Ann Arbor, and colleagues examined whether the effects of screening versus no screening on prostate cancer mortality differed between the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO). Mean lead times (MLTs) were estimated to account for increased incidence due to screening and diagnostic work-up in each group.

The researchers found that the estimated MLTs were similar in the intervention groups in the ERSPC and PLCO but longer in the PLCO than the ERSPC control group. In extended analyses there was no evidence of different effects of screening between the trials (P = 0.37 to 0.47); strong evidence showed increased benefit with MLT (P = 0.0027 to 0.0032). Per year of MLT, screening was estimated to confer a 7 to 9 percent reduction in the risk of prostate cancer death, translating into estimates of 25 to 31 percent and 27 to 32 percent lower risk for prostate cancer death for screening in the ERSPC and PLCO intervention groups, respectively, versus no screening.

"After differences in implementation and settings are accounted for, the ERSPC and PLCO provide compatible evidence that screening reduces prostate cancer mortality," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »